*** Welcome to piglix ***

Lurasidone

Lurasidone
Lurasidone.svg
Ball-and-stick model of the lurasidone molecule
Clinical data
Trade names Latuda
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611016
License data
Pregnancy
category
  • AU: B1
  • US: B (No risk in non-human studies)
Routes of
administration
Oral
ATC code N05AE05 (WHO)
Legal status
Legal status
Pharmacokinetic data
Bioavailability 9–19% (oral)
Metabolism Hepatic (CYP3A4-mediated)
Biological half-life 18 hours
Excretion Faecal (~80%), renal (~9%)
Identifiers
Synonyms SM-13,496
CAS Number 367514-87-2
PubChem (CID) 213046
IUPHAR/BPS 7461
ChemSpider 184739
UNII 22IC88528T YesY
ChEBI CHEBI:70735 YesY
ChEMBL CHEMBL1237021
ECHA InfoCard 100.225.187
Chemical and physical data
Formula C28H36N4O2S
Molar mass 492.68 g/mol
3D model (Jmol) Interactive image
Specific rotation [α]20D −59°
Melting point 176 to 178 °C (349 to 352 °F)
Solubility in water 45 mg/mL (20 °C)

Lurasidone /lɜːr.ˈræ.sɪ.dn/ (trade name Latuda) is an atypical antipsychotic developed by Dainippon Sumitomo Pharma and marketed by Sunovion in the USA. It has been approved for treatment of schizophrenia by the FDA since 2010. In the USA since 2013, it is also approved for the treatment of depressive episodes associated with bipolar I disorder as well as bipolar II disorder in adults when used alone or in combination with lithium, valproate, or lamotrigine.

Lurasidone is FDA approved for the treatment of schizophrenia since 2010 and depressive episodes associated with bipolar I disorder since 2013. It received regulatory approval in the UK in September 2014. In October 2014, NHS Scotland advised use of lurasidone for schizophrenic adults who have not seen improvements with previous antipsychotics due to problems that arise from weight gain or changes in metabolic pathways when taking other medications. It received EMA approval on January 24, 2014. It was launched in Canada for the treatment of schizophrenia in September 2012, Health Canada giving their Summary Basis of Decision (SBD) as favourable on October 15, 2012. European Commission has granted a marketing authorization for once-daily oral lurasidone for the treatment of schizophrenia in adults. It is approved for use in the EU.


...
Wikipedia

...